




## Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor

St.Peter DM, Steger JS, Patnaik JL, Davis N, Kahook MY, Seibold LK  
doi: 10.2147/MDER.S397654. Published 2023.




Nanodropper extends bottle-life by 2.6x



## Randomized Trial to Evaluate the Efficacy of the Nanodropper Device for Pupillary Dilation and Cycloplegia in Children

Hoppe CB, Yonamine S, Kao BW, Turner ML, Ou Y, Han Y, Keenan JD, Oatts JT  
doi: 10.1016/j.optha.2022.10.016. Published 2023.

Clinicaltrials.gov: NCT05274321




**In pediatric eyes:**  
Non-inferiority of mydriatic microdrops established for maximum pupil diameter



## The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter

Chow A, Choi J, Bacharach J  
doi: 10.2147/OPHTH.S504416. Published 2025.

Clinicaltrials.gov: NCT06689904



**In adult eyes:**  
Non-inferiority of mydriatic microdrops established for mean pupil diameter





## An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Steger JS, Durai I, Odayappan A, Raman R, Sruthi T, Song AJ, Puthuran G, Venkatesh R, Colantuoni E, Robin AL

doi: 10.2147/OPHTH.S504416. Published 2024.

Clinicaltrials.gov: NCT06689904



No between-group difference in IOP at any time point Microdrops reduced heart rate significantly less than conventional drops




## Twelve-Week Randomized, Controlled, Non-Inferiority Trial Evaluating the Safety and Efficacy of IOP-Lowering Microdrops Administered with the Nanodropper® Adaptor in Glaucoma Patients

Steger JS, Capó-Aponte JE, Papp A, Schulte AJ, Song AJ, Colantuoni E, Kelstrom JC


doi: DOI: 10.1097/j.jcrs.0000000000001823. Published 2026.

Clinicaltrials.gov: NCT05844384


### Superior IOP control



### Reduced Adverse Events



### Minimized EBE Events (Early Bottle Exhaustion)



n = 30 in conventional drop group, 29 in microdrops group; Error bars: Mean ± SEM; \* p<0.05.

### At 12 weeks, in stable glaucoma patients:

- Non-inferiority and superiority of microdrops established
- Microdrops decreased IOP from baseline by 1.6 mm Hg
- Microdrops decreased EBE prevalence by 80% and AE prevalence by 67%



← Download a PDF copy or access full publications at: [nanodropper.com/pubs](https://nanodropper.com/pubs)

Learn more: [nanodropper.com](https://nanodropper.com)  
Connect: [pro@nanodropper.com](mailto:pro@nanodropper.com)